Efforts to Copy Biotech Drugs Face Delays, Obstacles
The Wall Street Journal: Biotech Drugs Still Won't Copy
Much anticipated knockoff versions of costly biotech medicines are facing delays and obstacles that could cost patients and health systems billions in missed savings (Weaver, Whalen and Rockoff, 2/26).